Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas

Henry Brem, S. Piantadosi, P. C. Burger, M. Walker, R. Selker, N. A. Vick, K. Black, M. Sisti, S. Brem, G. Mohr, P. Muller, R. Morawetz, S. C. Schold

Research output: Contribution to journalArticle

Abstract

Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3·85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio=0·67, p=0·006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality=32 of 72 [44%] vs 47 of 73 [64%], p=0·02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.

Original languageEnglish (US)
Pages (from-to)1008-1012
Number of pages5
JournalThe Lancet
Volume345
Issue number8956
DOIs
StatePublished - Apr 22 1995

Fingerprint

Glioma
Polymers
Placebos
Carmustine
Safety
Drug Therapy
Brain Neoplasms
Survival
Glioblastoma
Random Allocation
Neoplasms
Prospective Studies
Mortality
Brain
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. / Brem, Henry; Piantadosi, S.; Burger, P. C.; Walker, M.; Selker, R.; Vick, N. A.; Black, K.; Sisti, M.; Brem, S.; Mohr, G.; Muller, P.; Morawetz, R.; Schold, S. C.

In: The Lancet, Vol. 345, No. 8956, 22.04.1995, p. 1008-1012.

Research output: Contribution to journalArticle

Brem, H, Piantadosi, S, Burger, PC, Walker, M, Selker, R, Vick, NA, Black, K, Sisti, M, Brem, S, Mohr, G, Muller, P, Morawetz, R & Schold, SC 1995, 'Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas', The Lancet, vol. 345, no. 8956, pp. 1008-1012. https://doi.org/10.1016/S0140-6736(95)90755-6
Brem, Henry ; Piantadosi, S. ; Burger, P. C. ; Walker, M. ; Selker, R. ; Vick, N. A. ; Black, K. ; Sisti, M. ; Brem, S. ; Mohr, G. ; Muller, P. ; Morawetz, R. ; Schold, S. C. / Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. In: The Lancet. 1995 ; Vol. 345, No. 8956. pp. 1008-1012.
@article{d494d1d577084aedaeac4e4e533df951,
title = "Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas",
abstract = "Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3·85{\%} carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio=0·67, p=0·006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50{\%} greater than in those treated with placebo (mortality=32 of 72 [44{\%}] vs 47 of 73 [64{\%}], p=0·02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.",
author = "Henry Brem and S. Piantadosi and Burger, {P. C.} and M. Walker and R. Selker and Vick, {N. A.} and K. Black and M. Sisti and S. Brem and G. Mohr and P. Muller and R. Morawetz and Schold, {S. C.}",
year = "1995",
month = "4",
day = "22",
doi = "10.1016/S0140-6736(95)90755-6",
language = "English (US)",
volume = "345",
pages = "1008--1012",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8956",

}

TY - JOUR

T1 - Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas

AU - Brem, Henry

AU - Piantadosi, S.

AU - Burger, P. C.

AU - Walker, M.

AU - Selker, R.

AU - Vick, N. A.

AU - Black, K.

AU - Sisti, M.

AU - Brem, S.

AU - Mohr, G.

AU - Muller, P.

AU - Morawetz, R.

AU - Schold, S. C.

PY - 1995/4/22

Y1 - 1995/4/22

N2 - Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3·85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio=0·67, p=0·006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality=32 of 72 [44%] vs 47 of 73 [64%], p=0·02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.

AB - Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3·85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio=0·67, p=0·006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality=32 of 72 [44%] vs 47 of 73 [64%], p=0·02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0028917333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028917333&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(95)90755-6

DO - 10.1016/S0140-6736(95)90755-6

M3 - Article

C2 - 7723496

AN - SCOPUS:0028917333

VL - 345

SP - 1008

EP - 1012

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8956

ER -